

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 014058-005630US

Assistant Commissioner for Patents
Washington, D.C. 20231

On MARCH 26, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Sharen Domino

AMDT

5/B

Linda

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

KINDSVOGEL *et al.*

Application No. 09/261,811 10/061,761

Filed: March 3, 1999

For: IMMUNE MEDIATORS AND RELATED METHODS

Examiner: DeCloudx, Amy

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Examiner's request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed December 4, 2000, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

In the Specification:

Please replace the paragraph beginning at page 5, line 20, with the following:

--Within still another embodiment the first linker DNA segment encodes GASAG (SEQ ID NO:29) or GGGGSGGGGSGGGGS (SEQ ID NO:36).--